Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | SELP | P16109 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.44 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951272 | 1.00 | S1PR1 (0.54) | S1PR1SELPGPR55ALDH1A1MAPT | |
| SCHEMBL9951800 | 0.99 | S1PR1 (0.53) | S1PR1SELPGPR55ALDH1A1MAPT | |
| SCHEMBL19616499 | 0.99 | S1PR1 (0.53) | S1PR1SELPGPR55ALDH1A1MAPT | |
| SCHEMBL8632106 | 0.97 | S1PR1 (0.52) | S1PR1SELPGPR55ALDH1A1MAPT | |
| SCHEMBL9951988 | 0.97 | S1PR1 (0.49) | S1PR1SELPDAGLAP2RY10GPR34 | |
| SCHEMBL17595343 | 0.97 | S1PR1 (0.49) | S1PR1SELPDAGLAP2RY10GPR34 | |
| SCHEMBL2340054 | 0.97 | S1PR1 (0.49) | S1PR1SELPDAGLAP2RY10GPR34 | |
| SCHEMBL8627715 | 0.91 | S1PR1 (0.46) | S1PR1SELPGPR55ALDH1A1MAPT | |
| SCHEMBL16964730 | 0.89 | P2RY10 (0.43) | S1PR1P2RY10GPR34 | |
| SCHEMBL9166758 | 0.88 | PLA2G2C (0.43) | MAPTDAGLAP2RY10GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2024216162-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4017537-A1 | SILK PERSONAL CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021035087-A1 | SILK PERSONAL CARE COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2021-02-25 | — | — | WO | claimed |
| WO-2020243047-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2020-12-03 | — | — | WO | claimed |
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216162-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2023212618-A1 | LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4255569-A1 | METHODS AND COMPOSITIONS FOR TREATING AN OPHTHALMIC CONDITION | Telios Pharma, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023172812-A1 | LIPOSOME-CONTAINING DIAGNOSTIC REAGENTS AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-4114968-A1 | COMPOSITIONS AND METHODS OF USING MODIFIED LIPOSOMES | Siemens Healthcare Diagnostics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4017537-A1 | SILK PERSONAL CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2020198657-A1 | RECOMBINANT SILK BASED PRODUCTS AND METHODS OF PREPARING THE SAME | EVOLVED BY NATURE, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020123656-A1 | METHODS AND COMPOSITIONS OF TREATING AN OPHTHALMIC CONDITION | KARTOS THERAPEUTICS (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-2654779-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | Ludwig Institute for Cancer Research, Ltd. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012088414-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-2410990-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | Marval Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010107990-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | MARVAL BIOSCIENCES, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-1742669-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | MARVEL THERAPEUTICS (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005107820-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | MARVEL THERAPEUTICS (US) | 2005-11-17 | — | — | WO | disclosed |